Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

NCT07509112 on ClinicalTrials.gov · last registry update 2026-06-26

A small phase 2 — 40 participants, against a typical 110. Due to report January 2027, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Efficacy Outcome (exploratory). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: NOT_YET_RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Kirby Institute
Sponsor type: Other Gov
Enrollment: 40
Started: 2026-09
Primary completion: 2027-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Efficacy Outcome (exploratory)

Conditions studied

Methamphetamine Use Disorder

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.